Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the effect on LDL cholesterol levels of converting patients who are receiving the cholesterol absorption inhibitor Zetia at a dose of 10 milligrams to 5 milligrams, when prescribed as a split 10 milligram tablet.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bronx VA Medical Center
• Treatments: Ezetimibe

Criteria

Inclusion Criteria:

• Subjects receiving ezetimibe 10 mg

• Subjects who have demonstrated compliance with ezetimibe as evidenced by the following Proportions of Days Covered patterns (which represent a PDC of more than 75%):

• 90 day prescriptions: Filled a ezetimibe prescription within the previous 4 months

• 60 day prescriptions: Filled a ezetimibe prescription within the previous 2.5 months

• 30 day prescriptions: Filled a ezetimibe prescription within the previous 1.5 months

• Patients willing and able to provide signed informed consent

Exclusion Criteria:

• Patients not receiving ezetimibe

• Patients receiving ezetimibe 5 milligrams

• Patients with a history of being titrated from ezetimibe 5 to 10 mg. Stroke,TIA, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass surgery, or major surgery within the 3 months

• Cancer undergoing active treatment

• Participation in any clinical study within the last 30 days

• Drug addiction or alcohol abuse within the past 6 months

• Patients unwilling or unable to provide informed consent

• Patients with poor compliance

• Women of childbearing potential